Q-omics provides the consensus-scored TRIM39-RPP21 profile across patient tissues and cancer cell-line models. TRIM39-RPP21 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRIM39-RPP21 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, TRIM39-RPP21 RNA expression shows 5,262 significant pathway-activity associations, with the highest sampling consensus in THCA. Together, these results highlight KIRP, BRCA, and THCA as cancer lineages where TRIM39-RPP21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM39-RPP21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM39-RPP21 survival associations across molecular data types. TRIM39-RPP21 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM39-RPP21 RNA expression–survival associations across cancer types. High TRIM39-RPP21 expression shows unfavorable associations in KIRP, UCEC, LGG, LUSC and LUAD, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRP as the clearest survival context for TRIM39-RPP21 RNA expression.
This table summarizes TRIM39-RPP21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM39-RPP21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM39-RPP21 shows lower tumor expression in KICH, THCA and LUSC and higher tumor expression in BRCA, PRAD and CHOL. The BRCA box plot shows higher TRIM39-RPP21 RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .010).
This table shows molecular features associated with TRIM39-RPP21 in patient tissues and cancer cell lines. In patient samples, TRIM39-RPP21 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM39-RPP21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
